Symdeko for six
THE US Food and Drug Administration has expanded the indication for Symdeko (tezacaftor/ivacaftor) tablets for the treatment of cystic fibrosis in paediatric patients aged six and up who have certain genetic mutations.
THE US Food and Drug Administration has expanded the indication for Symdeko (tezacaftor/ivacaftor) tablets for the treatment of cystic fibrosis in paediatric patients aged six and up who have certain genetic mutations.